Basel, 19 March 2020- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced we are working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced...
European site enrollment concerns near 80% An ongoing quantitative survey conducted by Continuum Clinical shows clinical research study sites are rapidly becoming more concerned about COVID-19-related interruptions to clinical trial recruitment and retention, with US...
Roche has collaborated with the US Food and Drug Administration (FDA) to conduct a Phase III clinical trial of Actemra/RoActemra (tocilizumab) in hospitalised adults with severe Covid-19 pneumonia. Actemra/RoActemra is an anti-IL-6 receptor biologic approved to treat...
A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle, WA, the United States National Institutes of Health...
– PROTECT Study Randomization to be Paused Temporarily in Response to the Ongoing Public Health Crisis – Company Reaffirms it is on Schedule to Complete PRV-031 (teplizumab) Rolling BLA Submission for Prevention or Delay of T1D in At-risk Individuals...
WESTLAKE VILLAGE, Calif., March 16, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and...
Email
Text